176 related articles for article (PubMed ID: 20919860)
1. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy.
Hashimoto K; Kobayashi Y; Asakura Y; Mori M; Azuma T; Maruyama D; Kim SW; Watanabe T; Tobinai K
Leuk Lymphoma; 2010 Oct; 51(10):1816-21. PubMed ID: 20919860
[TBL] [Abstract][Full Text] [Related]
2. Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma.
Venhuizen AC; Hustinx WN; van Houte AJ; Veth G; van der Griend R
Eur J Haematol; 2008 Mar; 80(3):275-6. PubMed ID: 18005387
[No Abstract] [Full Text] [Related]
3. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab.
Kurokawa T; Kaya H; Yoshida T
J Clin Exp Hematop; 2010; 50(2):159-62. PubMed ID: 21123974
[TBL] [Abstract][Full Text] [Related]
4. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
[No Abstract] [Full Text] [Related]
5. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders.
Obeid KM; Aguilar J; Szpunar S; Sharma M; del Busto R; Al-Katib A; Johnson LB
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):66-9. PubMed ID: 22000698
[TBL] [Abstract][Full Text] [Related]
6. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
[TBL] [Abstract][Full Text] [Related]
7. Low incidence of pneumocystis pneumonia utilizing PCR-based diagnosis in patients with B-cell lymphoma receiving rituximab-containing combination chemotherapy.
Barreto JN; Ice LL; Thompson CA; Tosh PK; Osmon DR; Dierkhising RA; Plevak MF; Limper AH
Am J Hematol; 2016 Nov; 91(11):1113-1117. PubMed ID: 27472910
[TBL] [Abstract][Full Text] [Related]
8. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
[TBL] [Abstract][Full Text] [Related]
9. Failure to prescribe pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database.
Lim PL; Zhou J; Ditangco RA; Law MG; Sirisanthana T; Kumarasamy N; Chen YM; Phanuphak P; Lee CK; Saphonn V; Oka S; Zhang F; Choi JY; Pujari S; Kamarulzaman A; Li PC; Merati TP; Yunihastuti E; Messerschmidt L; Sungkanuparph S;
J Int AIDS Soc; 2012 Jan; 15(1):1. PubMed ID: 22281054
[TBL] [Abstract][Full Text] [Related]
10. Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis.
Jiang X; Mei X; Feng D; Wang X
PLoS One; 2015; 10(4):e0122171. PubMed ID: 25909634
[TBL] [Abstract][Full Text] [Related]
11. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
[TBL] [Abstract][Full Text] [Related]
12. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.
Kolstad A; Holte H; Fosså A; Lauritzsen GF; Gaustad P; Torfoss D
Haematologica; 2007 Jan; 92(1):139-40. PubMed ID: 17229653
[TBL] [Abstract][Full Text] [Related]
14. [Pneumocystis pneumonia prophylaxis with low-dose trimethoprim/sulfamethoxazole during rituximab-containing chemotherapy].
Shimizu R; Sakemura R; Iwata S; Hayakawa H; Miyao K; Kajiguchi T
Rinsho Ketsueki; 2019; 60(5):365-371. PubMed ID: 31167996
[TBL] [Abstract][Full Text] [Related]
15. Pneumocystis jiroveci pneumonia (PCP) in patients receiving neoadjuvant and adjuvant anthracycline-based chemotherapy for breast cancer: incidence and risk factors.
Waks AG; Tolaney SM; Galar A; Arnaout A; Porter JB; Marty FM; Winer EP; Hammond SP; Baden LR
Breast Cancer Res Treat; 2015 Nov; 154(2):359-67. PubMed ID: 26420402
[TBL] [Abstract][Full Text] [Related]
16. Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia.
Maeda T; Babazono A; Nishi T; Matsuda S; Fushimi K; Fujimori K
Br J Haematol; 2015 Feb; 168(4):501-6. PubMed ID: 25266912
[TBL] [Abstract][Full Text] [Related]
17. Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia.
Beltz K; Kramm CM; Laws HJ; Schroten H; Wessalowski R; Göbel U
Klin Padiatr; 2006; 218(3):177-9. PubMed ID: 16688676
[TBL] [Abstract][Full Text] [Related]
18. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.
Haeusler GM; Slavin MA; Seymour JF; Lingaratnam S; Teh BW; Tam CS; Thursky KA; Worth LJ
Eur J Haematol; 2013 Aug; 91(2):157-63. PubMed ID: 23668894
[TBL] [Abstract][Full Text] [Related]
19. [Pneumocystis jiroveci pneumonia as a complication of glucocorticoid therapy for interstitial pneumonia].
Enomoto T; Azuma A; Matsumoto A; Nei T; Hiramatsu K; Abe S; Usuki J; Kudoh S
Nihon Kokyuki Gakkai Zasshi; 2005 Dec; 43(12):725-30. PubMed ID: 16457333
[TBL] [Abstract][Full Text] [Related]
20. Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome.
Sato M; Ito S; Ogura M; Kamei K; Miyairi I; Miyata I; Higuchi M; Matsuoka K
Pediatr Nephrol; 2013 Jan; 28(1):145-9. PubMed ID: 22948319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
